Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Martin Schiestl"'
Autor:
Thomas Stangler, Martin Schiestl
Publikováno v:
AAPS Open, Vol 5, Iss 1, Pp 1-6 (2019)
Abstract The comparison of quality attributes is a key element in the evaluation of both biosimilars and manufacturing process changes for biological medicines. Different statistical approaches are proposed to facilitate such evaluations. However, th
Externí odkaz:
https://doaj.org/article/84ba209ddfe34ffea3e970eb63bec6ab
Autor:
William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel, Cornelius Fritsch, Cornelia Vogelsang, Andreas Seidl, Hansjoerg Toll, Martin Schiestl, Johann Holzmann
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Abstract Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) r
Externí odkaz:
https://doaj.org/article/c7209dcd6ffd42fea8b0b256f819198c
Autor:
Peter Bias, Martin Schiestl, Julie Maréchal-Jamil, Gopinath M. Ranganna, Björn Capsius, Karsten Roth, Byoungin Jung, Michael Trieb, Keith Watson
Publikováno v:
Biodrugs
Since the first approval of a biosimilar medicinal product in 2006, scientific understanding of the features and development of biosimilar medicines has accumulated. This review scrutinizes public information on development programs and the contribut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49afff11b6ae61c4178adfd1883689c3
https://doi.org/10.1007/s40259-020-00422-1
https://doi.org/10.1007/s40259-020-00422-1
Autor:
M. Incurvati, Martin Schiestl, Federico Marcolini, Lukas Wild, Ronald Stärz, Fabio Giulii Capponi, Federico Caricchi, Alejandro Secades Rodriguez
Unmanned aerial vehicles are characterized by a set of requirements, like high efficiency, resiliency, and reliability that conflict with the other main requirement of high power density aimed at minimizing the overall weight and size. This article p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee1b28f81650db3b5cd58068166e494
http://hdl.handle.net/11573/1486272
http://hdl.handle.net/11573/1486272
Autor:
Martin Schiestl, Guerric Radiere, Thomas Pietzonka, Paul Obeng, Jonathan M. Spector, Christiaan Scott, Dzifa Dey, Bisola Ashiru, Andrew Cavey, Rajiv Shah, Edwin Nkansah
Publikováno v:
Trends in pharmacological sciences. 42(2)
Biologic drugs are reshaping clinical practice in various disciplines, even while access to them is imbalanced across global settings. In sub-Saharan Africa, biotherapeutics have potential roles to play in the treatment of a range of conditions that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::860f832ae0e483010b8192fc76bdf9f1
https://pubmed.ncbi.nlm.nih.gov/33358177
https://pubmed.ncbi.nlm.nih.gov/33358177
Publikováno v:
Biodrugs
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
High-quality, safe, and effective biosimilars have the potential to increase access to biological therapies worldwide and to reduce cancer care costs. The European Medicines Agency (EMA) was the first regulatory authority to establish legislative pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aefce5862cc163a75bd8ec0895dbd3d2
http://europepmc.org/articles/PMC5878200
http://europepmc.org/articles/PMC5878200
Autor:
Monika Schweigler, Xinghua Guo, Andreas Seidl, Martin Schiestl, Johann Holzmann, Thomas Stangler, William C. Lamanna, Hillel P. Cohen
Publikováno v:
Expert Opinion on Biological Therapy. 18:369-379
Introduction: Biopharmaceuticals are large protein based drugs which are heterogeneous by nature due to post translational modifications resulting from cellular production, processing and storage. Changes in the abundance of different variants over t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::710f6803786e1859fba35b456cf2a5e6
https://doi.org/10.1080/14712598.2018.1421169
https://doi.org/10.1080/14712598.2018.1421169
Publikováno v:
Supportive Care in Cancer
Biosimilars are biological medicines that have been shown to be similar to a reference biological medicine that has already been approved for use. Development of biosimilars is based on a “totality of evidence” approach that involves a series of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ef011dae1b3d2b45cdc909321e39b77
http://europepmc.org/articles/PMC6694091
http://europepmc.org/articles/PMC6694091
Autor:
Daniel Schneider, Martin Schiestl, William C. Lamanna, Katharina Heller, Raffaele Guerrasio, Cornelius Fritsch, Veronika Hampl
Publikováno v:
Journal of Oncology Pharmacy Practice
Purpose The purpose of this study was to evaluate the in-use physicochemical and biological stability of the Sandoz rituximab biosimilar, marketed under the trade names Rixathon® and Riximyo® in the European Union, upon preparation for intravenous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7f9845879c16ad1dc7f22f25047749
http://europepmc.org/articles/PMC6348458
http://europepmc.org/articles/PMC6348458
Publikováno v:
Drug Design, Development and Therapy
A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological medicine that has already been authorized for use. A science-based regulatory framework to ensure high-quality biosimilars has bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010758976882b616f3fcd7a73e2554fc
http://europepmc.org/articles/PMC5440034
http://europepmc.org/articles/PMC5440034